Optimizing the Long-Term Therapy with Eculizumab (ECU) for Atypical Hemolytic Uremic Syndrome (aHUS).

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Dr. K. C. Chaudhuri Foundation, co-published by Springer India Country of Publication: India NLM ID: 0417442 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 0973-7693 (Electronic) Linking ISSN: 00195456 NLM ISO Abbreviation: Indian J Pediatr Subsets: MEDLINE
    • Publication Information:
      Publication: [Mumbai] : Dr. K. C. Chaudhuri Foundation, co-published by Springer India
      Original Publication: New Delhi : All India Institute Of Medical Sciences
    • Subject Terms:
      Atypical Hemolytic Uremic Syndrome*/drug therapy; Humans ; Antibodies, Monoclonal, Humanized/therapeutic use ; Complement Factor H
    • References:
      Fakhouri F, Fila M, Provôt F, et al. Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. Clin J Am Soc Nephrol. 2017;12:50–9. (PMID: 10.2215/CJN.0644061627799617)
      Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31:15–39. (PMID: 10.1007/s00467-015-3076-825859752)
      Ariceta G. Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)- a question to be addressed in a scientific way. Pediatr Nephrol. 2019;34:943–9. (PMID: 10.1007/s00467-019-4192-730693384)
      Gurevich E, Landau D. Pharmacological management of atypical hemolytic uremic syndrome in pediatric patients: current and future. Paediatr Drugs. 2023;25:193–202. (PMID: 10.1007/s40272-022-00555-6366377209839393)
    • Grant Information:
      PRA 2019 University of Foggia; PRA 2021 University of Foggia
    • Accession Number:
      A3ULP0F556 (eculizumab)
      0 (Antibodies, Monoclonal, Humanized)
      80295-65-4 (Complement Factor H)
    • Publication Date:
      Date Created: 20230930 Date Completed: 20240118 Latest Revision: 20240118
    • Publication Date:
      20240118
    • Accession Number:
      10.1007/s12098-023-04817-0
    • Accession Number:
      37776486